Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals (NASDAQ: REGN) is a leading biotechnology innovator developing transformative treatments for serious diseases through advanced platforms like VelociSuite®. This page serves as the definitive source for official company announcements, research milestones, and therapeutic developments.
Investors and medical professionals will find curated updates including FDA approvals, clinical trial results, partnership announcements, and financial reports. Our aggregation ensures timely access to Regeneron's progress in oncology, immunology, rare diseases, and ophthalmic therapies.
All content is sourced directly from Regeneron's communications and verified financial disclosures. Bookmark this page to monitor the company's pipeline advancements, regulatory updates, and strategic collaborations that drive biopharmaceutical innovation.
Rhea-AI Summary
Medison Pharma (Medison) (NASDAQ: REGN) has announced an exclusive multi-national agreement with Regeneron Ireland DAC, a subsidiary of Regeneron Pharmaceuticals, to commercialize Libtayo (cemiplimab) in select European markets and additional markets worldwide. Libtayo is a leading PD-1 inhibitor approved for the treatment of certain patients with cutaneous squamous cell carcinoma, advanced basal cell carcinoma, advanced non-small cell lung cancer, and advanced cervical cancer in more than two dozen countries. The agreement aims to continue patient access to this important therapy and facilitate a seamless transition of commercialization activities to Medison during the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will report its Q4 and full year 2023 financial and operating results on February 2, 2024. The conference call and webcast will be held at 8:30 AM Eastern Time on the same day. Participants can access the live webcast on the company's website or register in advance for the telephone conference call. A replay and transcript will be available on the website for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the 'Investors & Media' page of Regeneron's website. A replay and transcript of the webcast will be archived on the Company's website for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has been included on the Dow Jones Sustainability World Index (DJSI World) for the fifth consecutive year, alongside its fourth consecutive inclusion on the Dow Jones Sustainability North America Index (DJSI North America). Regeneron's dedication to sustainability is reflected in its consistent rankings, acknowledging the top 10 percent of the world's most sustainable companies in each industry. Regeneron stands proud as one of only five biotechnology firms globally to make the list, ranking among the top 2 percent. The company's improvement areas in this year’s assessment were climate strategy, labor practice indicators, and tax strategy. Regeneron's commitment to corporate responsibility is further highlighted by its impressive performance across various top ESG ratings and rankings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) presented positive data for odronextamab in patients with relapsed/refractory follicular lymphoma (FL) from a pivotal Phase 2 trial (ELM-2) at the 65th American Society of Hematology (ASH) Annual Meeting. The data demonstrated an 80% objective response rate and a 73% complete response (CR), with a 23-month median duration of response and 24-month median duration of CR. Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced Phase 2 primary analysis results for odronextamab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) at the 65th American Society of Hematology (ASH) Annual Meeting. The data showed a 52% objective response rate (ORR) and 31% complete response (CR) in the pivotal Phase 2 trial, with additional positive results from the Phase 1 trial. The primary analysis demonstrated impressive response rates, including in high-risk subgroups, and the potential treatment option for patients with this aggressive blood cancer. Odronextamab is currently under regulatory review for the treatment of R/R DLBCL and R/R FL by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the primary endpoint analysis from the pivotal trial investigating linvoseltamab demonstrated high rates of deep and durable responses in patients with relapsed/refractory multiple myeloma. At a median duration of follow-up of 11 months, an objective response rate of 71% was observed, with 46% achieving a complete response or better. The regimen had a convenient, response-adapted administration schedule that enabled deep responders to go from every two-week to every four-week dosing. All patients treated with 200 mg experienced an adverse event, including 85% who experienced Grade ≥3 adverse events. Deaths due to treatment-emergent AEs on-treatment or within 30 days post last dose occurred in 14 patients (12%).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (REGN) presented encouraging Phase 1 dose-escalation data for REGN5668 (MUC16xCD28) in combination with Libtayo (cemiplimab) at the ESMO IO Congress 2023. Initial results show early clinical activity in patients with recurrent ovarian cancer, with a 21% stable disease rate and a 59% target lesion reduction from baseline in one patient. The combination demonstrated an acceptable safety profile with fatigue, nausea, and pain as the most common treatment-related adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
-
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will host a conference call and webcast on December 14, 2023, to provide an update on its hematology portfolio. This follows data updates presented at the 65th ASH Annual Meeting and Exposition. The webcast can be accessed on the company's website, and a replay will be available for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.09%
Tags
Rhea-AI Summary
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi's NOTUS trial for Dupixent in patients with COPD with type 2 inflammation showed a 34% reduction in exacerbations, rapid lung function improvement, and plans for a supplemental BLA submission by end of 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.03%
Tags
Regeneron Pharmaceuticals
Nasdaq:REGN
REGN Rankings
REGN Stock Data
60.05B
105.70M
1.58%
91.4%
2.35%
Biotechnology
Pharmaceutical Preparations
United States
TARRYTOWN